Пошук
Developing and implementing a Drug reduce University Diploma for health practitioners in Uruguay: challenges and future directions
In Uruguay, there is a shortage of trained professionals in drug prevention, intervention, and resolution of drug-related issues, particularly among health personnel in domains such as rehabilitation, prevention, schools, communities, and...
ATI Basics: SUD Treatment for Persons in the Justice System
Developing and implementing a Drug reduce University Diploma for health practitioners in Uruguay: challenges and future directions
ATI Basics: Fundamentals of Alternatives to Incarceration (ATI)
Can a "treatment specialist" also be seen as a "prevention specialist" and vice versa?
Pharmacological and Behavioral Treatment of Opioid Use Disorder
Abstract
Objective:
Opioid use disorder (OUD) in the United States has surged, with an estimated 2.5 million needing treatment. The aim of this article is to provide a clinical overview of the key pharmacological and behavioral treatments...
ATI Basics: Why Alternatives to Incarceration (ATI)?
Continental Training of Trainers (ToT) on the CHILD Curriculum and In-Person Training in Egypt
Children's drug use in Africa is a growing concern that requires urgent attention and comprehensive strategies. Understanding the complex factors influencing children's drug use and implementing effective prevention and intervention...
Continental Training of Trainers (ToT) on the CHILD Curriculum and In-Person Training in Egypt
Children's drug use in Africa is a growing concern that requires urgent attention and comprehensive strategies. Understanding the complex factors influencing children's drug use and implementing effective prevention and intervention...
Intervenciones en trastornos por usos de sustancias (TUS): una mirada desde la Psicología y la Neurociencia
Stimulant Use Webinar Series. Part I: About Amphetamine Type Stimulants and Stimulant Use Disorder
Pharmacological management of acute methamphetamine withdrawal
About the webinar:
This seminar provided an overview of Liam’s PhD studies, beginning with a systematic review and meta-analysis of previously researched pharmacological treatments for methamphetamine withdrawal.
It then proposed a novel...
Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder
Abstract
Importance Suicidal behavior is a significant clinical concern in individuals with borderline personality disorder (BPD), but the effectiveness of pharmacotherapy on reducing suicide risk has remained unknown.
Objective To...
Психоделіки сприяють пластичності, безпосередньо зв'язуючись з рецептором BDNF TrkB
Абстрактний
Психоделіки викликають швидкий і стійкий антидепресивний ефект і викликають нейропластичність, що нагадує ефекти клінічно схвалених антидепресантів. Нещодавно ми повідомляли, що фармакологічно різноманітні антидепресанти...
How alcohol consumption contributes to chronic pain
A team showed how both alcohol intake and alcohol withdrawal can lead to increased pain and hypersensitivity.
Chronic alcohol consumption may make people more sensitive to pain through two different molecular mechanisms -- one driven by...
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
La FDA aprueba una nueva opción de tratamiento con buprenorfina para el trastorno por consumo de opioides
Para publicación inmediata: 24 de mayo del 2023
Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi...
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review
Abstract
Objective
The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration–approved medications for treatment of opioid use disorder: methadone, buprenorphine...
Focal mu-opioid receptor activation promotes neuroinflammation and microglial activation in the mesocorticolimbic system: Alterations induced by inflammatory pain
Abstract
Microglia participates in the modulation of pain signaling. The activation of microglia is suggested to play an important role in affective disorders that are related to a dysfunction of the mesocorticolimbic system (MCLS) and are...